Recombinant GD2 (Naxitamab Biosimilar) antibody
Quick Overview for Recombinant GD2 (Naxitamab Biosimilar) antibody (ABIN7676126)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-GD2 Reference Antibody (naxitamab)
-
Sequence
- QVQLVESGPG VVQPGRSLRI SCAVSGFSVT NYGVHWVRQP PGKGLEWLGV IWAGGITNYN SAFMSRLTIS KDNSKNTVYL QMNSLRAEDT AMYYCASRGG HYGYALDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK,EIVMTQTPAT LSVSAGERVT ITCKASQSVS NDVTWYQQKP GQAPRLLIYS ASNRYSGVPA RFSGSGYGTE FTFTISSVQS EDFAVYFCQQ DYSSFGQGTK LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C
-
Characteristics
- Anti-GD2 Reference Antibody (naxitamab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: GD2 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- GD2 (Naxitamab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
Target
-